

Update in Internal Medicine 2026

Saturday, May 2 • 8 a.m. – 4 p.m.

UT Southwestern Medical Center, T. Boone Pickens Medical Education & Conference Center



Hypertrophic Cardiomyopathy

Natalie Tapaskar MD

*Assistant Professor; Medical Director of Hypertrophic Cardiomyopathy
Advanced Heart Failure, LVAD, and Transplant Cardiology*

UT Southwestern
Medical Center

Objectives

1. What is hypertrophic cardiomyopathy (HCM)?
2. What is the diagnostic algorithm for HCM and its phenocopies?
3. What is the natural history of HCM and who is at highest risk of adverse outcomes?
4. What to do if you suspect HCM at UTSW?


Not covered: Treatment algorithm of HCM

Objectives

- 1. What is hypertrophic cardiomyopathy (HCM)?**
2. What is the diagnostic algorithm for HCM and its phenocopies?
3. What is the natural history of HCM and who is at highest risk of adverse outcomes?
4. What to do if you suspect HCM at UTSW?

Left ventricular hypertrophy out of proportion to increased afterload


- **Imaging guided diagnosis**
- **Maximal end-diastolic wall thickness ≥ 15 mm anywhere in the left ventricle**
- **LVH =13-14 mm if:**
 - Have a family member with HCM or
 - The patient himself has a pathogenic/likely pathogenic sarcomere protein variant




Source: Fuster V, Walsh RA, Harrington RA: *Hurst's The Heart, 13th Edition*: www.accessmedicine.com
Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

HCM is highly prevalent: 1/200-1/500 worldwide

- 30-60% have identifiable sarcomere variants
 - >2000 individual variants in ~11 genes
 - Autosomal dominant inheritance
 - Polygenic factors
- Diagnosis **does not** require a family history of HCM or positive genetic testing



Disease of cardiac sarcomere



Imbalance in myosin head conformational states



More myosin in disordered relaxed state




More myosin-actin cross bridges



1. HYPERCONTRACTILITY
2. IMPAIRED RELAXATION
3. INCREASED ENERGY CONSUMPTION


Deranged myocytes at the cellular level



- **Cardiac myocytes are hypertrophied, disorganized, and separated by interstitial fibrosis**
- (A) Normal myocardium
- (B) Disorganized myocardial architecture in HCM
- (C) Myocyte disarray in HCM
- (D) Interstitial fibrosis (blue) in HCM

Numerous patterns of LVH are possible

- (A)** localized basal septal hypertrophy
- (B)** reverse curvature septal hypertrophy
- (C)** apical HCM
- (D)** concentric HCM
- (E)** mid-cavity obstruction with apical aneurysm
- (F)** other





ECG abnormalities present in 95% of patients with HCM


- LVH criteria
- Deep, narrow, dagger-like Q waves in lateral leads

Associated features:

- Left atrial enlargement
- WPW (short PR, delta wave)
- Arrhythmias
- Giant precordial T wave inversions (apical HCM)



Why does left ventricular hypertrophy matter clinically?



1. Small
2. Stiff
3. Hypercontractile


Obstructive HCM accounts for ~70% of HCM cases

DYNAMIC interplay between:

1. **Hypertrophied** basal interventricular septum
2. **Abnormalities of the mitral valve apparatus**, and
3. **Systolic anterior motion (SAM)** of the mitral valve leaflet


Which together narrow and obstruct the outflow tract during systole

Obstructive HCM



Thickened heart muscle restricting blood flow from the left ventricle

Non-obstructive HCM



Thickened heart muscle but blood flow not restricted

Eject-Obstruct-Leak

Drag forces on the anterior mitral leaflet are the dominant mechanism pushing it toward the LVOT

Venturi forces may contribute as a secondary amplifying effect once the LVOT is already significantly narrowed and flow velocities are high

SAM dependent MR: Eject-Obstruct-Leak concept

LVOT narrowing

- Septal hypertrophy and anterior displacement of papillary muscles
- Elongated mitral leaflets and chordae
- Anterior displacement of the mitral apparatus

Early systole
Rapid
LV ejection

Venturi and drag forces distal to site of MV leaflets coaptation

Early
to
Mid-systole

systolic anterior motion of MV leaflet with mitral leaflet-septal contact

Mid-systole


MV leaflets malcoaptation causing an interleaflet gap

Mid-systole

Mitral regurgitation with posteriorly directed jet



Numerous mechanisms drive symptom burden



HCM can present with a constellation of nonspecific symptoms

Exertional symptoms

- Chest pain
- Fatigue
- Dizziness


Arrhythmic symptoms

- Palpitations
- Presyncope
- Syncope

Heart failure symptoms

- Dyspnea
- Orthopnea
- Peripheral edema

Post prandial symptoms present in ~35% of HCM patients





Suspect HCM when there is a family history of early SCD

Family history

- Unexplained or sudden death in a first degree relative <50 years old


Systolic ejection murmur that increases with decreased preload suggests dynamic LVOT obstruction



Objectives

1. What is hypertrophic cardiomyopathy (HCM)?
- 2. What is the diagnostic algorithm for HCM and its phenocopies?**
3. What is the natural history of HCM and who is at highest risk of adverse outcomes?
4. What to do if you suspect HCM at UTSW?

Diagnostic algorithm



Left ventricular hypertrophy out of proportion to increased afterload


**LVH must be in the absence of another cardiac, systemic, or metabolic disease capable of producing the magnitude of LVH in a given patient

Hypertension

Athletic Heart

Aortic Stenosis

Cardiac Amyloidosis/Other Phenocopies



(A)


Source: Fuster V, Walsh RA, Harrington RA: *Hurst's The Heart, 13th Edition*: www.accessmedicine.com
Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

Hypertension coexists in 40-60% of adults with HCM



Aspect	HCM Alone	HCM with Hypertension
Imaging Features	More likely asymmetric LVH	Mixed patterns, concentric LVH also common

Hypertension coexists in 40-60% of adults with HCM

Hypertension as a modifier of disease expression in HCM




Athletic remodeling depends on dynamic and static load



HCM hearts have smaller LV cavity sizes than athletic hearts


When to suspect HCM instead of athletic remodeling

- ✓ Patchy or asymmetric pattern of LVH
- ✓ LV cavity deficiency (<45 mm)
- ✓ Marked left atrium enlargement
- ✓ Abnormal diastolic function
- ✓ Wall thickness does NOT regress with de-training




Valvular aortic stenosis can co-occur with HCM

- Unknown disease prevalence
- Diagnostic challenge that requires identifying the level of obstruction
- **191 patients undergoing myectomy + surgical AVR**
 - Older than isolated HCM
 - No difference in mortality compared to age-matched general population



Cardiac amyloidosis is a must not miss diagnosis




Suspect cardiac amyloidosis in the setting of extra-cardiac manifestations


When to suspect cardiac amyloid instead of HCM

- ✓ History of bilateral carpal tunnel syndrome (5-10 years prior to cardiac diagnosis)
- ✓ Lumbar or cervical spinal stenosis
- ✓ Spontaneous biceps tendon rupture
- ✓ Hip/knee replacements (~80% of ATTR patients have orthopedic interventions)
- ✓ Peripheral neuropathy
- ✓ Autonomic dysfunction (orthostatic hypotension, gastroparesis, urinary incontinence)
- ✓ Intolerance to vasodilating antihypertensives
- ✓ **Low voltage QRS on EKG despite LVH (25-40% of cases only)**


Diagnostic algorithm




HCM mimics - diagnostic clues



Diagnostic algorithm



Not all LVOT /mid-cavitary obstruction is HCM



Dynamic

Cirrhosis (~25% on stress testing)

Takotsubo/stress cardiomyopathy (~15-25% of patients)

Cardiac amyloidosis (~4% of patients)

Extreme hypovolemic shock (even in absence of underlying structural heart disease)


Post-cardiac surgery (after MVR/MVr)

Acute myocardial infarction


Objectives

1. What is hypertrophic cardiomyopathy (HCM)?
2. What is the diagnostic algorithm for HCM and its phenocopies?
- 3. What is the natural history of HCM and who is at highest risk of adverse outcomes?**
4. What to do if you suspect HCM at UTSW?

Natural history is highly variable



Phenotypes are not mutually exclusive



Maron et al. JACC 2022



Dual phenotyping: (1) Symptom phenotype and (2) Sudden cardiac death risk

- Wide phenotypic expression and symptom burden
- Higher lifelong risk of adverse events (mortality, HF, stroke, ventricular arrhythmias, AF) in:
 - (1) patients with pathogenic/likely pathogenic sarcomere variants
 - (2) patients diagnosed earlier in life

Even asymptomatic patients can be high risk for sudden cardiac death

Symptom burden \neq sudden death risk

NYHA class I patients have 49% risk of adverse 10-year outcomes




	n	1-Year Risk	5-Year Risk	10-Year Risk
NYHA functional class I	598	7%	28%	49%
NYHA functional class II	641	16%	44%	66%

Composite outcome


- NYHA III/IV
- LVEF<50%
- Afib
- CVA
- Ventricular arrhythmias SRT
- Heart transplant
- LVAD
- Death

Must risk stratify every patient for arrhythmogenic sudden death


Family history
Unexplained syncope
***Massive LVH ≥ 30 mm**
Apical aneurysm
EF <50%




Decreasing rates of sudden death globally in post-ICD era



HCM with LVEF<35% represents a particularly high-risk population




Time from initial evaluation to development of HCM with LVEF <50%: 7.5% incidence rate after 15 years



Females have higher all-cause mortality when controlling for age, sarcomere variant, LVEF, and LAVi

SRT
F>M




NYHA III-IV
F>M

Ventricular arrhythmias
F=M

Mortality
F>M

Decreasing HCM-related mortality in contemporary era



Take home points

- HCM is highly prevalent: 1/200-1/500 worldwide
- Diagnosis via imaging of LVH ≥ 15 mm
- Must rule out mimics (cardiac amyloid)
- Risk stratify for SCD via high-risk criteria
 - Family history of SCD
 - Massive LVH >30 mm
 - Apical aneurysm
 - LVEF $<50\%$
 - Personal history of unexplained syncope
- Overall mortality has improved in contemporary era

Objectives

1. What is hypertrophic cardiomyopathy (HCM)?
2. What is the diagnostic algorithm for HCM and its phenocopies?
3. What is the natural history of HCM and who is at highest risk of adverse outcomes?
- 4. What to do if you suspect HCM at UTSW?**

UTSW is an HCM Center of Excellence



UTSouthwestern
Medical Center.

[Find a Doctor](#)

[Conditions & Treatments](#)

[Locations](#)

[Academics](#)

[Search](#)



[New Patient Appointment](#)

or [214-645-8000](tel:214-645-8000)

Hypertrophic Cardiomyopathy


[Comprehensive Heart and Vascular Center](#)

UTSouthwestern
Medical Center

UTSW is an HCM Center of Excellence




Myectomy Alcohol Septal ablation



RIGHTS RESERVED.

Cardiac myosin inhibitors



Heart Transplant



Electrophysiology

Advanced exercise testing

Invasive hemodynamics

Genetic counseling

Comprehensive cardiac imaging

Clinical Trials

Thank you

Natalie.tapaskar@utsouthwestern.edu